chymase


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

chy·mo·sin

(kī'mō-sin),
An aspartic proteinase structurally homologous with pepsin, formed from prochymosin; the milk-curdling enzyme obtained from the glandular layer of the stomach of the calf. Acts on a single peptide bond (-Phe-Met-) in κ-casein.
Synonym(s): chymase, pexin, rennase, rennet, rennin

chymase

[kī′mās]
a serine protease present in human mast cells, most prominent in skin and connective tissue, where it can cleave angiotensin and stimulate mucous glands.

chymase

(kī′mās)
An enzyme in gastric juice that accelerates the action of the pancreatic enzymes.

chymase

see RENNIN.
References in periodicals archive ?
Mast cell chymase and tryptase in abdominal aortic aneurysm formation.
Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas.
Mast cell tryptases and chymases in inflammation and host defense.
2 million increase in revenue and net interest income for the first quarter compared to the same period in 1994 was primarily due to (i) increased revenues from the Amgen and Pharmacia collaborations entered into in 1993 for the development of small molecule mimetics of erythropoietin and human growth factors, respectively and (ii) revenues from the company's collaborative agreement with Bayer AG, entered into in November, 1994, for the development of inhibitors of tryptase and chymase.
Arris' inflammation program focuses on development of novel therapeutics based on inhibiting tryptase and chymase.
NASDAQ:ARRS) Monday announced a five-year collaborative agreement with Bayer, AG, Leverkusen, Germany, covering the company's inflammation program including therapeutic and diagnostic use for tryptase, chymase and their inhibitors.
After an extensive evaluation, Bayer has agreed with us that our program focused on the inhibition of tryptase and chymase may offer an important new approach to the development of therapeutics for asthma, rhinitis and other inflammatory diseases.
Arris's inflammation program focuses on development of novel therapeutics based on inhibiting tryptase and chymase.
Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice.